Gastroenterology/Bariatrics Clinical Trial - Abbvie - M15-991

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03104413

The objective of Study M15-991 is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active CD.

Drug

Drug: Risankizumab IV, Risankizumab SC, & Placebo for IV

Trial Type

Interventional

Age Range

18 years or older

Phase

Phase 3

Condition

Weight loss Crohn's Disease

Keywords

M15-991 | Crohn's Disease | Abbvie